Beneficial and adverse effects of testosterone on the cardiovascular system in men

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 11, 2013, Pages 4300-4310

  Ruige, Johannes B ^a   Ouwens, D Margriet ^a,b   Kaufman, Jean Marc ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BRAIN NATRIURETIC PEPTIDE; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ABDOMINAL AORTA ANEURYSM; ANDROGEN THERAPY; ANGINA PECTORIS; AROMATIZATION; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR SYSTEM; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; FAINTNESS; GENETIC POLYMORPHISM; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; HYPOGONADISM; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG EMBOLISM; MALE; NONHUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; THORAX PAIN; THROMBOSIS; VASCULAR DISEASE;

AGED; AGING; ANDROGENS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MEN'S HEALTH; MIDDLE AGED; RISK FACTORS; TESTOSTERONE;

EID: 84887495625     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1970     Document Type: Review

References (120)

1. Gluud C. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. The Copenhagen Study Group for Liver Diseases. Hepatology. 1986;6: 807-813.
2. Brockenbrough AT, DittrichMO,Page ST, Smith T, Stivelman JC, Bremner WJ. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis. 2006;47: 251-262.
3. Hall GM, Larbre JP, Spector TD, Perry LA, Da Silva JA. A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol. 1996;35: 568-573.
4. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci. 2004;59: 75-78.
5. Chapman IM, Visvanathan R, Hammond AJ, et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr. 2009;89: 880-889.
6. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363: 109-122.
7. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95: 639-650.
8. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Lowdose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102: 1906-1911.
9. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo- controlled, randomized study. J Am Coll Cardiol. 2009;54: 919-927.
10. Jones TH, Arver S, Behre HM, et al; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34: 828-837.
11. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73: 602-612.
12. Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. 2011;8:2079- 2089.
13. Ho CC, Tong SF, Low WY, et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int. 2012;110: 260-265.
14. Legros JJ, Meuleman EJ, Elbers JM, Geurts TB, Kaspers MJ, Bouloux PM; Study 43203 Investigators. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol. 2009;160: 821-831.
15. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299: 39-52.
16. Snyder PJ, Peachey H, Berlin JA, et al. Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age. Am J Med. 2001;111: 255-260.
17. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26: 833-876.
18. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. Cell. 2005;122: 751-762.
19. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011;97: 870-875.
20. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165: 675-685.
21. Lee DK, Chang C. Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab. 2003;88: 4043-4054.
22. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev. 2002;23: 175-200.
23. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003;26: 76-83.
24. Zitzmann M, Brune M, Kornmann B, et al. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab. 2001; 86: 4867-4873.
25. Heinlein CA, Chang C. The roles of androgen receptors and androgen- binding proteins in nongenomic androgen actions. Mol Endocrinol. 2002;16: 2181-2187.
26. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24: 313-340.
27. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev. 2003;24: 183-217.
28. Torkler S, Wallaschofski H, Baumeister SE, et al. Inverse association between total testosterone concentrations, incident hypertension and blood pressure. Aging Male. 2010;14: 176-182.
29. Simon D, CharlesMA,Lahlou N, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo- controlled trial. Diabetes Care. 2001;24: 2149-2151.
30. Chignalia AZ, Schuldt EZ, Camargo LL, et al. Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src-dependent pathways. Hypertension. 2012;59:1263- 1271.
31. Barton M, Prossnitz ER, Meyer MR. Testosterone and secondary hypertension: new pieces to the puzzle. Hypertension. 2012;59: 1101-1103.
32. Davis DD, Ruis AL, Yanes LL, et al. Testosterone supplementation in male obese Zucker rats reduces body weight and improves insulin sensitivity but increases blood pressure. Hypertension. 2012; 59: 726-731.
33. Sieveking DP, Lim P, Chow RW, et al. A sex-specific role for androgens in angiogenesis. J Exp Med. 2010;207: 345-352.
34. Mayr M, Niederseer D, Niebauer J. From bench to bedside: what physicians need to know about endothelial progenitor cells. Am J Med. 2011;124: 489-497.
35. Foresta C, Caretta N, Lana A, et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006;91: 4599-4602.
36. Foresta C, Zuccarello D, De Toni L, Garolla A, Caretta N, Ferlin A. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin Endocrinol (Oxf). 2008;68: 284-289.
37. Cai J, Hong Y, Weng C, Tan C, Imperato-McGinley J, Zhu YS. Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism.AmJ Physiol Heart Circ Physiol. 2011;300:H1210-H1221.
38. Fadini GP, Albiero M, Cignarella A, et al. Effects of androgens on endothelial progenitor cells in vitro and in vivo. Clin Sci (Lond). 2009;117: 355-364.
39. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101: 948-954.
40. Zitzmann M, Brune M, Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab. 2002;87: 5030-5037.
41. Malkin CJ, Jones RD, Jones TH, Channer KS. Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond). 2006; 111: 265-274.
42. Kang SM, Jang Y, Kim Ji, et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol. 2002;89: 862-864.
43. Webb CM, McNeill JG, Hayward CS, de Ziegler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary artery disease. Circulation. 1999;100: 1690-1696.
44. Webb CM, Elkington AG, Kraidly MM, Keenan N, Pennell DJ, Collins P. Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease.AmJ Cardiol. 2008;101: 618-624.
45. Ruige JB. Does low testosterone affect adaptive properties of adipose tissue in obese men? Arch Physiol Biochem. 2011;117: 18-22.
46. Ruige JB, Bekaert M, Lapauw B, et al. Sex steroid-induced changes in circulating monocyte chemoattractant protein-1 levels may contribute to metabolic dysfunction in obese men. J Clin Endocrinol Metab. 2012;97:E1187-E1191.
47. Haffner SM, Valdez RA. Endogenous sex hormones: impact on lipids, lipoproteins, and insulin. Am J Med. 1995;98:40S-47S.
48. Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab. 2011;96: 885-893.
49. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010; 95: 2560-2575.
50. Høst C, Gormsen LC, Christensen B, et al. Independent effects of testosterone on lipid oxidation and VLDL-TG production: a randomized, double-blind, placebo-controlled, crossover study. Diabetes. 2013;62: 1409-1416.
51. Ferenchick G, Schwartz D, Ball M, Schwartz K. Androgenic-anabolic steroid abuse and platelet aggregation: a pilot study in weight lifters. Am J Med Sci. 1992;303: 78-82.
52. Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. 1995;91: 2742-2747.
53. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94: 2353-2359.
54. Abbott RD, Launer LJ, Rodriguez BL, et al. Serum estradiol and risk of stroke in elderly men. Neurology. 2007;68: 563-568.
55. Lakshman KM, Kaplan B, Travison TG, et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010;95: 3955-3964.
56. Glueck CJ, Goldenberg N, Budhani S, et al. Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia. Transl Res. 2011;158: 225-234.
57. Nordstrom SM, Weiss EJ. Sex differences in thrombosis. Expert Rev Hematol. 2008;1: 3-8.
58. Ruige JB, Rietzschel ER, De Buyzere ML, et al Asklepios Investigators. Modest opposite associations of endogenous testosterone and oestradiol with left ventricular remodelling and function in healthy middle-aged men. Int J Androl. 2011;34:e587-e593.
59. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;284:H1560-H1569.
60. Nahrendorf M, Frantz S, Hu K, et al. Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc Res. 2003;57: 370-378.
61. Loyer X, Oliviero P, Damy T, et al. Effects of sex differences on constitutive nitric oxide synthase expression and activity in response to pressure overload in rats. Am J Physiol Heart Circ Physiol. 2007;293:H2650- H2658.
62. Wang M, Wang Y, Abarbanell A, et al. Both endogenous and exogenous testosterone decrease myocardial STAT3 activation and SOCS3 expression after acute ischemia and reperfusion. Surgery. 2009;146: 138-144.
63. Wang C, Chan V, Tse TF, Yeung RT. Effect of acute myocardial infarction on pituitary-testicular function. Clin Endocrinol (Oxf). 1978;9: 249-253.
64. Lam CS, Cheng S, Choong K, et al. Influence of sex and hormone status on circulating natriuretic peptides. J AmColl Cardiol. 2011; 58: 618-626.
65. Khan AM, Cheng S, Magnusson M, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community- based studies. J Clin Endocrinol Metab. 2011;96: 3242-3249.
66. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnostic criteria. J Am Coll Cardiol. 2011;57: 802-812.
67. James AF, Choisy SC, Hancox JC. Recent advances in understanding sex differences in cardiac repolarization. Prog Biophys Mol Biol. 2007;94: 265-319.
68. Zhang Y, Ouyang P, Post WS, et al. Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi- Ethnic Study of Atherosclerosis. Am J Epidemiol. 2011;174: 403-411.
69. Schwartz JB, Volterrani M, Caminiti G, et al. Effects of testosterone on theQ-Tinterval in oldermenand olderwomenwith chronic heart failure. Int J Androl. 2011;34:e415-e421.
70. Bigi MA, Aslani A, Aslani A. Short QT interval: a novel predictor of androgen abuse in strength trained athletes. Ann Noninvasive Electrocardiol. 2009;14: 35-39.
71. Van Noord C, Rodenburg EM, Stricker BH. Invited commentary: sex-steroid hormones and QT-interval duration. Am J Epidemiol. 2011;174: 412-415.
72. Price JF, Lee AJ, Fowkes FG. Steroid sex hormones and peripheral arterial disease in the Edinburgh Artery Study. Steroids. 1997;62: 789-794.
73. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87: 3632-3639.
74. MullerM,van den BeldAW,BotsML,Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109: 2074-2079.
75. Eller NH, Netterstrøm B, Allerup P. Progression in intima media thickness - the significance of hormonal biomarkers of chronic stress. Psychoneuroendocrinology. 2005;30: 715-723.
76. Hougaku H, Fleg JL, Najjar SS, et al. Relationship between androgenic hormones and arterial stiffness, based on longitudinal hormone measurements. Am J Physiol Endocrinol Metab. 2006; 290:E234-E242.
77. Tivesten A, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, Fagerberg B. Circulating estradiol is an independent predictor of progression of carotid artery intima-media thickness in middleaged men. J Clin Endocrinol Metab. 2006;91: 4433-4437.
78. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96: 3007-3019.
79. Cauley JA, Gutai JP, Kuller LH, Dai WS. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol. 1987;60: 771-777.
80. Phillips GB, Yano K, StemmermannGN.Serum sex hormone levels and myocardial infarction in the Honolulu Heart Program. Pitfalls in prospective studies on sex hormones. J Clin Epidemiol. 1988; 41: 1151-1156.
81. Vikan T, Schirmer H, Njølstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol. 2009;161: 435-442.
82. Yarnell JW, Beswick AD, Sweetnam PM, Riad-Fahmy D. Endogenous sex hormones and ischemic heart disease in men. The Caerphilly prospective study. Arterioscler Thromb. 1993;13: 517-520.
83. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med. 2007;167: 1252-1260.
84. Hautanen A, Mänttäri M, Manninen V, et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis. 1994;105: 191-200.
85. Arnlöv J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006; 145: 176-184.
86. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007; 116: 2694-2701.
87. Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210: 232-236.
88. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58: 1674-1681.
89. Menke A, Guallar E, Rohrmann S, et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol. 2010; 171: 583-592.
90. Hyde Z, Norman PE, Flicker L, et al.Lowfree testosterone predicts mortality from cardiovascular disease but not other causes: the Health inMenStudy. J Clin Endocrinol Metab. 2012;97: 179-189.
91. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.BMCMed. 2013;11:108.
92. Jick SS, Hagberg KW. The risk of adverse outcomes in association with use of testosterone products: a cohort study using the UKbased general practice research database. Br J Clin Pharmacol. 2013;75: 260-270.
93. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114: 1829-1837.
94. Wehr E, Pilz S, Boehm BO, März W, Grammer T, Obermayer- Pietsch B. Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail. 2011;13: 482-488.
95. Toma M, McAlister FA, Coglianese EE, et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail. 2012;5: 315-321.
96. Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS. Effect of testosterone therapy onQTdispersion in men with heart failure. Am J Cardiol. 2003;92: 1241-1243.
97. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161: 443-449.
98. Ezaki K, Nakagawa M, Taniguchi Y, et al. Gender differences in the ST segment: effect of androgen-deprivation therapy and possible role of testosterone. Circ J. 2010;74: 2448-2454.
99. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92: 405-413.
100. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care. 2000;23: 490-494.
101. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009;361: 1152-1163.
102. Peter A, Kantartzis K,MachannJ, et al. Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes. 2010;59: 3167-3173.
103. Raven G, de Jong FH, Kaufman JM, de Ronde W. In men, peripheral estradiol levels directly reflect the action of oestrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab. 2006;91: 3324-3328.
104. Ohlsson C, Wallaschofski H, Lunetta KL, et al. Genetic determinants of serum testosterone concentrations in men. PLoS Genet. 2011;7:e1002313.
105. Vanbillemont G, Bogaert V, De Bacquer D, et al. Polymorphisms of the SHBG gene contribute to the interindividual variation of sex steroid hormone blood levels in young, middle-aged and elderly men. Clin Endocrinol (Oxf). 2009;70: 303-310.
106. Crabbe P, Bogaert V, De Bacquer D, Goemaere S, Zmierczak H, Kaufman JM. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab. 2007;92: 3604-3610.
107. Lapauw B, Goemaere S, Crabbe P, Kaufman JM, Ruige JB. Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men? Eur J Endocrinol. 2007;156: 395-401.
108. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92: 3844-3853.
109. Eyben FE, Graugaard C, Vaeth M. All-cause mortality and mortality of myocardial infarction for 989 legally castrated men. Eur J Epidemiol. 2005;20: 863-869.
110. Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone. Nature. 1993;366(6452):215.
111. Rothman KJ. Modern Epidemiology. Boston, MA: Little, Brown and Company; 1986.
112. Tsai EC, Boyko EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as a predictor of increased visceral fat in Japanese- American men. Int J Obes Relat Metab Disord. 2000;24: 485-491.
113. Haring R, Völzke H, Felix SB, et al. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes. 2009;58: 2027-2031.
114. Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middleaged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90: 712-719.
115. Woodard G, Ahmed S, Podelski V, Hernandez-Boussard T, Presti J Jr, Morton JM. Effect of Roux-en-Y gastric bypass on testosterone and prostate-specific antigen. Br J Surg. 2012;99: 693-698.
116. Pitteloud N, Hardin M, Dwyer AA, et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005;90: 2636-2641.
117. Vandenplas G, De Bacquer D, Calders P, et al. Endogenous oestradiol and cardiovascular disease in healthy men: a systematic review and meta-analysis of prospective studies. Heart. 2012;98: 1478-1482.
118. Rochira V, Carani C. Aromatase deficiency in men: a clinical perspective. Nat Rev Endocrinol. 2009;5: 559-568.
119. Mauvais-Jarvis F. Estrogen sulfotransferase: intracrinology meets metabolic diseases. Diabetes. 2012;61: 1353-1354.
120. Woodhouse LJ, Gupta N, Bhasin M, et al. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab. 2004;89: 718-726.